Journal Mobile Options
Table of Contents
Vol. 12, No. 5-6, 2009
Issue release date: August 2009
Public Health Genomics 2009;12:291–307
(DOI:10.1159/000214920)

Epidemiology of Mucosal Human Papillomavirus Infection and Associated Diseases

Trottier H. · Burchell A.N.
aDepartments of Oncology and Epidemiology and Biostatistics, McGill University, and bDepartment of Social and Preventive Medecine, University of Montréal, Ste-Justine Hospital, Montreal, Que., Canada

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

This article describes the epidemiology of mucosal human papillomavirs (HPV) in adults and children, its mode of transmission and its associated diseases. Over 40 genotypes of HPV infect the epithelial lining of the anogenital tract and other mucosal areas of the body. HPV is the most common sexually transmitted infection globally, with high prevalences found in both females and males. The predominant route of transmission is via sexual contact, although mother-to-child transmission is also possible. HPV infection may exist asymptomatically or may induce the formation of benign or malignant tumours in the genital, oral or conjunctival mucosa. Although most infections clear spontaneously, those that persist result in substantial morbidity and invoke high costs associated with the treatment of clinically relevant lesions. Some 13–18 mucosal HPV types are considered to have high oncogenic potential. HPV is recognized unequivocally as the main causal factor for cervical cancer, and is further responsible for a substantial proportion of many other anogenital neoplasms and head and neck cancers. Infections with HPV types that have low oncogenic risk, such as HPV-6 and 11, are associated with benign lesions of the anogenital areas known as condylomata acuminata (genital warts), oral papillomas, conjunctival papillomas, as well as low-grade squamous intra-epithelial lesions of the cervix. Perinatally acquired HPV can also cause recurrent respiratory papillomatosis in infants and young children. The implementation of HPV vaccination therefore has the potential to prevent a substantial proportion of HPV-related disease in the future.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Parkin DM: The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030–3044.
  2. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of papillomaviruses. Virology 2004;324:17–27.
  3. Trottier H, Franco EL: The epidemiology of genital human papillomavirus infection. Vaccine 2006;24(suppl 1):S1–S15.
  4. International Agency for Research on Cancer: Monographs on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses, vol 90. Lyon, IARC, 2007.
  5. Baseman JG, Koutsky LA: The epidemiology of human papillomavirus infections. J Clin Virol 2005;32(suppl 1):S16–S24.
  6. Bosch FX, de Sanjosé S: Human papillomavirus and cervical cancer: burden and assessment of causality. J Natl Cancer Inst Monogr 2003;31:3–13.
  7. Franco EL, Villa LL, Richardson H, Rohan T, Ferenczy A: Epidemiology of cervical human papillomavirus infection; in Franco E, Monsonego J (eds): New Developments in Cervical Cancer Screening and Prevention. Oxford, Blackwell Science, 1997, pp 14–22.
  8. Gjooen K, Olsen AO, Magnus P, Grinde B, Sauer T, Orstavik I: Prevalence of human papillomavirus in cervical scrapes, as analyzed by PCR, in a population-based sample of women with and without cervical dysplasia. APMIS 1996;104:68–74.
  9. Herrero R, Castle PE, Schiffman M, et al: Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005;191:1796–1807.
  10. International Agency for Research on Cancer (IARC): Epidemiology of infection: human papillomaviruses. Carcinog Risk Chem Hum 1995;64:60–65.
  11. Richardson H, Kelsall G, Tellier P, et al: The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003;12:485–490.
  12. Schiffman MH: Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 1992;84:394–398.
  13. Kjaer SK, Chackerian B, van den Brule AJ, et al: High-risk human papillomavirus is sexually transmitted: evidence from a follow up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 2001;10:101–106.
  14. de Sanjosé S, Diaz M, Castellsagué, et al: Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453–459.
  15. Trottier H, Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL: Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2006;15:1274–1280.
  16. de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ, Kenter G, Offringa R, van der Burg SH: Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004;64:5449–5455.
  17. Thomas KK, Hughes JP, Kuypers JM, et al: Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000;182:1097–1102.
  18. Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Ning L, Killeen J, Kamemoto L, Hernandez BY: Acquisition of anal human papillomavirus (HPV) infection in women: the Hawaii HPV Cohort study. J Infect Dis 2008;197:957–966.
  19. Giuliano AR, Nielson CM, Flores R, Dunne EF, Abrahamsen M, Papenfuss MR, Markowitz LE, Smith D, Harris RB: The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV Detection in Men Study. J Infect Dis 2007;196:1146–1152.
  20. Giuliano AR, Lu B, Nielson CM, Flores R, Papenfuss MR, Lee JH, Abrahamsen M, Harris RB: Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 2008;198:827–835.
  21. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR: Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 2006;194:1044–1057.
  22. Weaver BA, Feng Q, Holmes KK, Kiviat N, Lee SK, Meyer C, Stern M, Koutsky LA: Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis 2004;189:677–685.
  23. Partridge J, Koutsky L: Genital human papillomavirus infection in men. Lancet Infect Dis 2006;6:21–31.
  24. Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjosé S, Kjaer SK, Muñoz N, Schiffman M, Bosch FX: Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008;26(S10):K17–K28.
  25. Chin-Hong PV, Vittinghoff E, Cranston RD, et al: Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis 2004;190:2070–2076.
  26. Palefsky JM, Holly EA, Ralston ML, Jay N: Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998;177:361–367.
  27. Giuliano AR, Lazcano E, Villa LL, et al: The Human Papillomavirus Infection in Men (HIM) Study: HPV prevalence and type-distribution among men residing in Brazil, Mexico and the US. Cancer Epidemiol Biomarkers Prev 2008;17:2036–2043.
  28. Muñoz N, Méndez F, Posso H, Molano M, van den Brule AJ, Ronderos M, Meijer C, Muñoz A; Instituto Nacional de Cancerologia HPV Study Group: Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004;190:2077–2087.
  29. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, et al: Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415–1423.
  30. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278–285.
  31. Giuliano AR, Papenfuss M, Abrahamsen M, Inserra P: Differences in factors associated with oncogenic and nononcogenic human papillomavirus infection at the United States–Mexico border. Cancer Epidemiol Biomarkers Prev 2002;11:930–934.
  32. Partridge JM, Hughes JP, Feng Q, Winer RL, Weaver BA, Xi LF, Stern ME, Lee SK, O’Reilly SF, Hawes SE, Kiviat NB, Koutsky LA: Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis 2007;196:1128–1136.
  33. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423–428.
  34. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS: Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831–1836.
  35. Schiffman M, Castle PE: Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med 2003;127:930–934.
  36. Trottier H, Mahmud S, Prado JC, Sobrinho JS, Costa MC, Rohan TE, Villa LL, Franco EL: Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis 2008;197:1436–1447.
  37. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME, et al: Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235–240.
  38. Brisson J, Bairati I, Morin C, Fortier M, Bouchard C, Christen A, Bernard P, Roy M, Meisels A: Determinants of persistent detection of human papillomavirus DNA in the uterine cervix. J Infect Dis 1996;173:794–799.
  39. Liaw KL, Hildesheim A, Burk RD, Gravitt P, Wacholder S, Manos MM, Scott DR, Sherman ME, Kurman RJ, Glass AG, Anderson SM, Schiffman M: A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001;183:8–15.
  40. Molano M, Van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A, Meijer CJ, Munoz N, Franceschi S: Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003;158:486–494.
  41. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD: The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337:76–84.
  42. Ahdieh L, Klein RS, Burk R, et al: Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 2001;184:682–690.
  43. Syrjanen S, Shabalova I, Petrovichev N, et al: Factors predicting persistence of high-risk human papillomavirus (HPV) infections in women prospectively followed-up in three New Independent States (NIS) of the former Soviet Union. Eur J Gynaecol Oncol 2005;26:491–498.
  44. Richardson H, Abrahamowicz M, Tellier PP, et al: Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev 2005;14:1149–1156.
  45. Castle PE, Schiffman M, Herrero R, et al: A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005;191:1808–1816.
  46. Perrons C, Jelley R, Kleter B, Quint W, Brink N: Detection of persistent high risk human papillomavirus infections with hybrid capture II and SPF10/LiPA. J Clin Virol 2005;32:278–285.
  47. Rousseau MC, Abrahamowicz M, Villa LL, Costa MC, Rohan TE, Franco EL: Predictors of cervical coinfection with multiple human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2003;12:1029–1037.
  48. Kjaer SK, Munk C, Winther JF, Jorgensen HO, Meijer CJLM, van den Brule AJC: Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev 2005;14:1528–1533.
  49. Lajous M, Mueller N, Cruz-Valdez A, Aguilar LV, Franceschi S, Hernandez-Avila M, Lazcano-Ponce E: Determinants of prevalence, acquisition, and persistence of human papillomavirus in health Mexican miltary men. Cancer Epidemiol Biomarkers Prev 2005;14:1710–1716.
  50. Miller CS, Johnstone BM: Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982–1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:622–635.
  51. Summersgill KF, Smith EM, Levy BT, Allen JM, Haugen TH, Turek LP: Human papillomavirus in the oral cavities of children and adolescents. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:62–69.
  52. Giovannelli L, Campisi G, Lama A, Giambalvo O, Osborn J, Margiotta V, Ammatuna P: Human papillomavirus DNA in oral mucosal lesions. J Infect Dis 2002;185:833–836.
  53. Nagpal JK, Patnaik S, Das BR: Prevalence of high-risk human papilloma virus types and its association with P53 codon 72 polymorphism in tobacco addicted oral squamous cell carcinoma (OSCC) patients of Eastern India. Int J Cancer 2002;97:649–653.
  54. do Sacramento PR, Babeto E, Colombo J, Cabral Ruback MJ, Bonilha JL, Fernandes AM, Pereira Sobrinho JS, de Souza FP, Villa LL, Rahal P: The prevalence of human papillomavirus in the oropharynx in healthy individuals in a Brazilian population. J Med Virol 2006;78:614–618.
  55. Newall AT, Brotherton JM, Quinn HE, McIntyre PB, Backhouse J, Gilbert L, Esser MT, Erick J, Bryan J, Formica N, MacIntyre CR: Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin Infect Dis 2008;46:1647–1655.
  56. Michael KM, Waterboer T, Sehr P, Rother A, Reidel U, Boeing H, Bravo IG, Schlehofer J, Gartner BC, Pawlita M: Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathogens 2008;4:e1000091.
  57. Hariri S, Dunne EF, Sternberg M, Unger ER, Meadows KS, Karem KL, Markowitz LE: Seroepidemiology of human papillomavirus type 11 in the United States: results from the Third National Health and Nutrition Examination Survey, 1991–1994. Sex Transm Dis 2008;35:298–303.
  58. Thompson DL, Douglas JM, Foster M, Hagensee ME, DiGiuseppi C, Baron AE, Cameron JE, Spencer TC, Zenilman J, Malotte CK, Bolan G, Kamb ML, Peterman TA; for the Project RESPECT Study Group: Seroepidemiology of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States. J Infect Dis 2004;190:1563–1574.
  59. Skjeldestad FE, Mehta V, Sings HL, Øvreness T, Turpin J, Su L, Boerckel P, Roberts C, Bryan J, Jansen KU, Esser MT, Liaw KL: Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics. Acta Obstet Gynecol Scand 2008;87:81–88.
  60. Nonnenmacher B, Hubbert NL, Kirnbauer R, Shah KV, Munoz N, Bosch FX, et al: Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. J Infect Dis 1995;172:19–24.
  61. Park JS, Park DC, Kim CJ, Ahn HK, Um SJ, Park SN, et al: HPV-16-related proteins as the serologic markers in cervical neoplasia. Gynecol Oncol 1998;69:47–55.
  62. Heim K, Widschwendter A, Pirschner G, Awerkiew S, Christensen ND, Bergant A, Marth C, Hopfl R: Antibodies to human papillomavirus 16 L1 virus-like particles as independent prognostic marker in cervical cancer. Am J Obstet Gynecol 2002;186:705–711.
  63. Rigoni-Stern D: Fatti Statistici Relativi alle Mallattie Cancrose che Servirono di Base alle Poche Cose dette dal Doti. G Servire Progr Pathol Terap 1842;2:507–517.
  64. Rotkin ID: A comparison review of key epidemiological studies in cervical cancer related to current searches for transmissible agents. Cancer Res 1973;33:1353–1367.
  65. Winer RL, Feng Q, Hughes JP, O’Reilly S, Kiviat SB, Koutsky LA: Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 2008;197:279–282.
  66. Oriel JD: Natural history of genital warts. Br J Vener Dis 1971;47:1–13.
  67. Burchell AN, Winer RL, de Sanjosé S, Franco EL: Epidemiology and transmission dynamics of genital human papillomavirus infection. Vaccine 2006;24:S52–S61.
  68. Winer RL, Koutsky LA: Genital human papillomaviruses; in Holmes KK, et al (eds): Sexually Transmitted Diseases, ed 4. New York, McGraw Hill Medical, 2008, pp 489–508.
  69. Moscicki AB, Hills NK, Shiboski S, Darragh TM, Jay N, Powell K, et al: Risk factors for abnormal anal cytology in young heterosexual women. Cancer Epidemiol Biomarkers Prev 1999;8:173–178.
  70. Bleeker MC, Hogewoning CJ, Berkhof J, Voorhorst FJ, Hesselink AT, van Diemen PM, van den Brule AJ, Snijders PJ, Meijer CJ: Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clin Infect Dis 2005;41:612–620.
  71. Baken LA, Koutsky LA, Kuypers J, Kosorok MR, Lee SK, Kiviat NB, Holmes KK: Genital human papillomavirus infection among male and female sex partners: prevalence and type-specific concordance. J Infect Dis 1995;171:429–432.
  72. Burchell AN, Richardson H, Mahmud S, Trottier H, Tellier PP, Hanley J, et al: Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol 2006;163:534–543.
  73. Barnabas R, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett G: Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006;3:e138.
  74. Hernandez BY, Wilkens LR, Zhu X, Thompson P, McDuffie K, Shvetsov YB, Kamemoto LE, Killeen J, Ning L, Goodman MT: Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis 2008;14:888–894
  75. Manhart LE, Koutsky LA: Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 2002;29:725–735.
  76. Winer RL, Hughes JP, Feng Q, O’Reilly S, Kiviat NB, Holmes KK, Koutsky LA: Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006;354:2645–2654.
  77. Collins SI, Mazloomzadeh S, Winter H, Blomfield P, Baily A, Young LS, Woodman CBJ: High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 2002;109:96–98.
  78. Bosch FX, Burchell AN, Schiffman M, et al: Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26(S10):K1–K16.
  79. Edwards S, Carne C: Oral sex and the transmission of viral STIs. Sex Transm Infect 1998;74:6–10.
  80. Sonnex C, Strauss S, Gray JJ: Detection of human papillomavirus DNA on the fingers of patients with genital warts. Sex Transm Infect 1999;75:317–319.
  81. Gervaz P, Allal AS, Villiger P, Buhler L, Morel P: Squamous cell carcinoma of the anus: another sexually transmitted disease. Swiss Med Wkly 2003;133:353–359.
  82. Marrazzo JM, Stine K, Koutsky LA: Genital human papillomavirus infection in women who have sex with women: a review. Am J Obstet Gynecol 2000;183:770–774.
  83. Smith EM, Swarnavel S, Ritchie JM, Wang D, Haugen TH, Turek LP: Prevalence of human papillomavirus in the oral cavity/oropharynx in a large population of children and adolescents. Ped Infect Dis J 2007;26:836–840.
  84. Pao CC, Tsai PL, Chang YL, Hsiet TT, Jin JY: Non sexual papillomaviruses transmission routes. Lancet 1992;339:1479–1480.
  85. Cason J, Kaye J, Pakarian F, Raju KS, Best JM: HPV-16 transmission. Lancet 1995;345:197–198.
  86. Cason J, Mant CA: High-risk mucosal human papillomavirus infections during infancy and childhood. J Clin Virol 2005;32:S52–S58.
  87. Syrjänen S, Puranen M: Human papillomavirus infections in children: the potential role of maternal transmission. Crit Rev Oral Biol Med 2000;11:259–274.
  88. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA: Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218–226.
  89. Kojima A, Maeda H, Kurahashi N, Sakagami G, Kubo K, Yoshimoto H, Kameyama Y: Human papillomaviruses in the normal oral cavity of children in Japan. Oral Oncol 2003;39:821–828.
  90. Rice PS, Mant C, Cason J, Bible JM, Muir P, Kell B, Best JM: High prevalence of human papillomavirus type 16 infection among children. J Med Virol 2000;61:70–75.
  91. Hajek EF: Contribution to the etiology of laryngeal papilloma in children. J Laryngol Otol 1956;70:166–168.
  92. Sedlacek TV, Lindheim S, Eder C, Hasty L, Woodland M, Ludomirsky A, Rando RF: Mechanism for human papillomavirus transmission at birth. Am J Obstet Gynecol 1989;161:55–59.
  93. Puranen MH, Yliskoski MH, Saarikoski SV, Syrjänen KJ, Syrjänen SM: Exposure of an infant to cervical human papillomavirus infection of the mother is common. Am J Obstet Gynecol 1997;176:1039–1045.
  94. Kaye JN, Cason J, Pakarian FB, Jewers RJ, Kell B, Bible J, Raju KS, Best JM: Viral load as a determinant for transmission of human papillomavirus type 16 from mother to child. J Med Virol 1994;44:415–421.
  95. Tseng CJ, Liang CC, Soong YK, Pao CC: Perinatal transmission of human papillomavirus in infants: relationship between infection rate and mode of delivery. Obstet Gynecol 1998;91:92–96.
  96. Chaterjee R, Mukhopadhyay D, Murmu N, Mitra PK: Correlation between human papillomavirus DNA detection in maternal cervical smears and buccal swabs of infants. Indian J Exp Biol 1998;36:199–202.
  97. Rice PS, Cason J, Best JM, Banatvala JE: High risk genital papillomavirus infections are spread vertically. Rev Med Virol 1999;9:15–21.
  98. Armbruster-Moraes E, Ioshimoto LM, Leao E, Zugaib M: Detection of human papillomavirus deoxyribonucleic acid sequences in amniotic fluid during different periods of pregnancy. Am J Obstet Gynecol 1993;169:1074.
  99. Pao CC, Lin SS, Lin CY, Maa JS, Lai CH, Hsieh TT: Identification of human papillomavirus DNA sequences in peripheral blood mononuclear cells. Am J Clin Pathol 1991;95:540–546.
  100. Gomez LM, Ma Y, Ho C, Mcgrath CM, Nelson DB, Parry S: Placental infection with human papillomavirus is associated with spontaneous preterm delivery. Hum Reprod 2008;23:709–715.
  101. Favre M, Majewski S, De Jesus N, Malejczyk M, Orth G, Jablonska S: A possible vertical transmission of human papillomavirus genotypes associated with epidermodysplasia verruciformis. J Invest Dermatol 1998;111:333–336.
  102. Sarkola M, Rintala M, Grénman S, Syrjänen S: Human papillomavirus DNA detected in breast milk. Pediatr Infect Dis J 2008;27:557–558.
  103. Smith EM, Ritchie JM, Yankowitz J, Wang D, Turek LP, Haugen TH: HPV prevalence and concordance in the cervix and oral cavity of pregnant women. Infect Dis Obstet Gynecol 2004;12:45–56.
  104. Winer RL, Koutsky LA: Delivering reassurance to parents: perinatal human papillomavirus transmission is rare. Sex Transm Dis 2004;31:63–64.
  105. Rintala MA, Grénman SE, Puranen MH, Isolauri E, Ekblad U, Kero PO, Syrjänen SM: Transmission of high-risk human papillomavirus (HPV) between parents and infant: a prospective study of HPV in families in Finland. J Clin Microbiol 2005;43:376–381.
  106. Rintala MA, Grénman SE, Järvenkylä ME, Syrjänen KJ, Syrjänen SM: High-risk types of human papillomavirus (HPV) DNA in oral and genital mucosa of infants during their first 3 years of life: experience from the Finnish HPV Family Study. Clin Infect Dis 2005;41:1728–1733.
  107. Dunne EF, Karem KL, Sternberg MR, Stone KM, Unger ER, Reeves WC, Markowitz LE: Seroprevalence of human papillomavirus type 16 in children. J Infect Dis 2005;191:1817–1819.
  108. Heim K, Hudelist G, Geier A, Szedenik H, Christensen ND, Concin N, Bergant A, Volgger B, Czerwenka K, Höpfl R: Type-specific antiviral antibodies to genital human papillomavirus types in mothers and newborns. Reprod Sci 2007;14:806–814.
  109. Marais DJ, Sampson CC, Urban MI, Sitas F, Wiliamson AL: The seroprevalence of IgG antibodies to human papillomavirus (HPV) types HPV-16, HPV-18, and HPV-11 capsid-antigens in mothers and their children. J Med Virol 2007;79:1370–1374.
  110. Chow CW, Tabrizi SN, Tiedemann K, Waters KD: Squamous cell carcinomas in children and young adults: a new wave of a very rare tumor? J Pediatr Surg 2007;42:2035–2039.
  111. Ferlay J, Bray F, Pisani P, Parkin DM: GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0. Lyon, IARC Press, 2004.
  112. Pisani P, Parkin DM, Bray F, Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18–29.
  113. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, Scott DR, Sherman ME, Kurman RJ, Wacholder S, et al: Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958–964.
  114. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) study group. J Natl Cancer Inst 1995;87:796–802.
  115. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12–19.
  116. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518–527.
  117. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63–73.
  118. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL: Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001;286:3106–3114.
  119. Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CJ: Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002;325:572.
  120. Spence AR, Franco EL, Ferenczy A: The role of human papillomavirus in cancer. Am J Cancer 2005;4:49–64.
  121. Melbye M, Rabkin C, Frisch M, Biggar RJ: Changing patterns of anal cancer incidence in the United States, 1940–1989. Am J Epidemiol 1994;139:772–780.
  122. Frisch M, Melbye M, Moller H: Trends in incidence of anal cancer in Denmark. BMJ 1993;306:419–422.
  123. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR: Anal cancer incidence and survival: the SEER experience, 1973–2000. Cancer 2004;101:281–288.
  124. Palefsky JM: Human papillomavirus-related tumors. AIDS 2000;14(suppl 3):S189–S195.
  125. Ryan DP, Compton CC, Mayer RJ: Carcinoma of the anal canal. N Engl J Med 2000;342:792–800.
  126. Palefsky JM, Holly EA, Gonzales J, Berline J, Ahn DK, Greenspan JS: Detection of human papillomavirus DNA in anal intraepithelial neoplasia and anal cancer. Cancer Res 1991;51:1014–1019.
  127. Frisch M, Glimelius B, van den Brule AJ, Wohlfahrt J, Meijer CJ, Walboomers JM, Goldman S, Svensson C, Adami HO, Melbye M: Sexually transmitted infection as a cause of anal cancer. N Engl J Med 1997;337:1350–1358.
  128. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, Carter JJ, Porter PL, Galloway DA, McDougall JK: Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004;101:270–280.
  129. Muñoz N, Castellsagué X, de González AB, Gissmann L: Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24:S1–S10.
  130. Daling JR, Madeleine MM, Schwartz SM, Shera KA, Carter JJ, McKnight B, Porter PL, Galloway DA, McDougall JK, Tamimi H: A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 2002;84:263–270.
  131. Al-Ghamdi A, Freedman D, Miller D, Poh C, Rosin M, Zhang L, Gilks CB: Vulvar squamous cell carcinoma in young women: a clinicopathologic study of 21 cases. Gynecol Oncol 2002;84:94–101.
  132. Hørding U, Junge J, Daugaard S, Lundvall F, Poulsen H, Bock JE: Vulvar squamous cell carcinoma and papillomaviruses: indications for two different etiologies. Gynecol Oncol 1994;52:241–246.
  133. Cubilla AL, Velazques EF, Reuter VE, et al: Warty (condylomatous) squamous cell carcinoma of the penis: a report of 11 cases and proposed classification of ‘verruciform’ penile tumors. Am J Surg Pathol 2000;24:505–512.
  134. Cubilla AL, Reuter VE, Gregoire L, et al: Basaloid squamous cell carcinoma: a distinctive human papilloma virus-related penile neoplasm: a report of 20 cases. Am J Surg Pathol 1998;22:755–761.
  135. Rubin MA, Kleter B, Zhou M, Ayala G, Cubilla AL, Quint WG, Pirog EC: Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 2001;159:1211–1218.
  136. Heideman DA, Waterboer T, Pawlita M, Delis-van Diemen P, Nindl I, Leijte JA, Bonfrer JM, Horenblas S, Meijer CJ, Snijders PJ: Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J Clin Oncol 2007;25:4550–4556.
  137. Ferreux E, Lont AP, Horenblas S, et al: Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus. J Pathol 2003;201:109–118.
  138. Maden C, Sherman KJ, Beckmann AM, Hislop TG, Teh CZ, Ashley RL, Daling JR: History of circumcision, medical conditions, and sexual activity and risk of penile cancer. J Natl Cancer Inst 1993;85:19–24.
  139. Ragin CC, Modugno F, Gollin SM: The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 2007;86:104–114.
  140. Kreimer AR, Clifford GM, Boyle P, Franceschi S: Human papillomavirus types in head and neck SCCs worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467–475.
  141. Syrjanen S: Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 2005;32:S59–S66.
  142. Aguilera-Barrantes I, Magro C, Nuovo GJ: Verruca vulgaris of the vulva in children and adults: a nonvenereal type of vulvar wart. Am J Surg Pathol 2007;31:529–535.
  143. Insinga RP, Glass AG, Rush BB: Pap screening in a U.S. health plan. Cancer Epidemiol Biomarkers Prev 2004;13:355–360.
  144. Boyd AS: Condylomata acuminata in the pediatric population. Am J Dis Child 1990;144:817–824.
  145. Castro TP, Bussoloti Filho I: Prevalence of human papillomavirus (HPV) in oral cavity and oropharynx. Braz J Otorhinolaryngol 2006;72:272–282.
  146. Wiatrak BJ, Wiatrak DW, Broker TR, Lewis L: Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope 2004;114(suppl 104):1–23.
  147. Derkay CS: Reccurrent respiratory papillomatosis. Laryngoscope 2001;111:57–69.
  148. Stamataki S, Nikolopoulos TP, Korres S, Felekis D, Tzangaroulakis A, Ferekidis E: Juvenile recurrent respiratory papillomatosis: still a mystery disease with difficult management. Head Neck 2007;29:155–162.
  149. Reeves WC, Ruparelia SS, Swanson KI, Derkay CS, Marcus A, Unger ER: National registry for juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2003;129:976–982.
  150. Derkay CS, Wiatrak B: Reccurrent respiratory papillomatososis: a review. Laryngoscope 2008;118:1236–1247.
  151. Doyle DJ, Gianoli GJ, Espinola T, Miller RH: Recurrent respiratory papillomatosis: juvenile versus adult forms. Laryngoscope 1994;104:523–527.
  152. Woisard V, Flores P, Icart J, Bessède JP, Guerrier B, Traissac L, Pessey JJ: Is laryngeal papillomatosis always juvenile? (In French). Rev Laryngol Otol Rhinol (Bord) 1997;118:259–261.
  153. Sjö NC, von Buchwald C, Cassonnet P, Norrild B, Prause JU, Vinding T, Heegaard S: Human papillomavirus in normal conjunctival tissue and in conjunctival papilloma: types and frequencies in a large series. Br J Ophthalmol 2007;91:1014–1015.
  154. Van Doornum GJ, Prins M, Juffermans LH, et al: Regional distribution and incidence of human papillomavirus infections among heterosexual men and women with multiple sexual partners: a prospective study. Genitourin Med 1994;70:240–246.
  155. McDonnell JM, McDonnell PJ, Sun YY: Human papillomavirus DNA in tissues and ocular surface swabs of patients with conjunctival epithelial neoplasia. Invest Ophthalmol Vis Sci 1992;33:184–189.
  156. Tabrizi SN, McCurrach FE, Drewe RH, Borg AJ, Garland SM, Taylor HR: Human papillomavirus in corneal and conjunctival carcinoma. Aust NZ J Ophthalmol 1997; 25:211–215.
  157. Scott IU, Karp CL, Nuovo GJ: Human papillomavirus 16 and 18 expression in conjunctival intraepithelial neoplasia. Ophthalmology 2002;109:542–547.
  158. Nakamura Y, Mashima Y, Kameyama K, Mukai M, Oguchi Y: Detection of human papillomavirus infection in squamous tumours of the conjunctiva and lacrimal sac by immunohistochemistry, in situ hybridisation, and polymerase chain reaction. Br J Ophthalmol 1997;81:308–313.
  159. Moubayed P, Mwakyoma H, Schneider DT: High frequency of human papillomavirus 6/11, 16, and 18 infections in precancerous lesions and squamous cell carcinoma of the conjunctiva in subtropical Tanzania. Am J Clin Pathol 2004;122:938–943.
  160. Ateenyi-Agaba C, Weiderpass E, Smet A, Dong W, Dai M, Kahwa B, Wabinga H, Katongole-Mbidde E, Franceschi S, Tommasino M: Epidermodysplasia verruciformis human papillomavirus types and carcinoma of the conjunctiva: a pilot study. Br J Cancer 2004;90:1777–1779.
  161. Eng HL, Lin TM, Chen SY, Wu SM, Chen WJ: Failure to detect human papillomavirus DNA in malignant epithelial neoplasms of conjunctiva by polymerase chain reaction. Am J Clin Pathol 2002;117:429–436.
  162. Palazzi MA, Erwenne CM, Villa LL: Detection of human papillomavirus in epithelial lesions of the conjunctiva. Sao Paulo Med J 2000;118:125–130.
  163. Cupp MR, Malek RS, Goellner JR, Espy MJ, Smith TF: Detection of human papillomavirus DNA in primary squamous cell carcinoma of the male urethra. Urology 1996;48:551–555.
  164. Wiener JS, Walther PJ: A high association of oncogenic human papillomaviruses with carcinomas of the female urethra: polymerase chain reaction-based analysis of multiple histological types. J Urol 1994;151:49–53.
  165. Barghi MR, Hajimohammadmehdiarbab A, Moghaddam SM, Kazemi B: Correlation between human papillomavirus infection and bladder transitional cell carcinoma. BMC Infect Dis 2005;5:102.
  166. Wiwanitkit V: Urinary bladder carcinoma and human papilloma virus infection, an appraisal of risk. Asian Pac J Cancer Prev 2005;6:217–218.
  167. Aynaud O, Tranbaloc P, Orth G: Lack of evidence for a role of human papillomaviruses in transitional cell carcinoma of the bladder. J Urol 1998;159:86–90.
  168. Sur M, Cooper K, Allard U: Investigation of human papillomavirus in transitional cell carcinomas of the urinary bladder in South Africa. Pathology 2001;33:17–20.
  169. Westenend PJ, Stoop JA, Hendriks JG: Human papillomaviruses 6/11, 16/18 and 31/33/51 are not associated with squamous cell carcinoma of the urinary bladder. BJU Int 2001;88:198–201.
  170. Youshya S, Purdie K, Breuer J, Proby C, Sheaf MT, Oliver RT, Baithun S: Does human papillomavirus play a role in the development of bladder transitional cell carcinoma? A comparison of PCR and immunohistochemical analysis. J Clin Pathol 2005;58:207–210.
  171. Chen YC, Chen JH, Richard K, Chen PY, Christiani DC: Lung adenocarcinoma and human papillomavirus infection. Cancer 2004;15:1428–1436.
  172. Ciotti M, Giuliani L, Ambrogi V, Ronci C, Benedetto A, Mineo TC, Syrjänen K, Favalli C: Detection and expression of human papillomavirus oncogenes in non-small cell lung cancer. Oncol Rep 2006;16:183–189.
  173. Fei Y, Yang J, Hsieh WC, Wu JY, Wu TC, Goan YG, Lee H, Cheng YW: Different human papillomavirus 16/18 infection in Chinese non-small cell lung cancer patients living in Wuhan, China. Jpn J Clin Oncol 2006;36:274–279.
  174. Castillo A, Aguayo F, Koriyama C, Shuyama K, Akiba S, Herrera-Goepfert R, Carrascal E, Klinge G, Sánchez J, Eizuru Y: Human papillomavirus in lung carcinomas among three Latin American countries. Oncol Rep 2006;15:883–888.
  175. Cheng YW, Wu MF, Wang J, Yeh KT, Goan YG, Chiou HL, Chen CY, Lee H: Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res 2007;67:10686–10693.
  176. Aguayo F, Castillo A, Koriyama C, Higashi M, Itoh T, Capetillo M, Shuyama K, Corvalan A, Eizuru Y, Akiba S: Human papillomavirus-16 is integrated in lung carcinomas: a study in Chile. Br J Cancer 2007;97:85–91.
  177. Nadji SA, Mokhtari-Azad T, Mahmoodi M, Yahyapour Y, Naghshvar F, Torabizadeh J, Ziaee AA, Nategh R: Relationship between lung cancer and human papillomavirus in north of Iran, Mazandaran province. Cancer Lett 2007;248:41–46.
  178. Kaya H, Kotiloğlu E, Inanli S, Ekicioğlu G, Bozkurt SU, Tutkun A, Küllü S: Prevalence of human papillomavirus (HPV) DNA in larynx and lung carcinomas. Pathologica 2001;93:531–534.
  179. Brouchet L, Valmary S, Dahan M, Didier A, Galateau-Salle F, Brousset P, Degano B: Detection of oncogenic virus genomes and gene products in lung carcinoma. Br J Cancer 2005;92:743–746.
  180. Coissard CJ, Besson G, Polette MC, Monteau M, Birembaut PL, Clavel CE: Prevalence of human papillomaviruses in lung carcinomas: a study of 218 cases. Mod Pathol 2005;18:1606–1609.
  181. Giuliani L, Jaxmar T, Casadio C, Gariglio M, Manna A, D’Antonio D, Syrjanen K, Favalli C, Ciotti M: Detection of oncogenic viruses SV40, BKV, JCV, HCMV, HPV and p53 codon 72 polymorphism in lung carcinoma. Lung Cancer 2007;57:273–281.
  182. Park MS, Chang YS, Shin JH, Kim DJ, Chung KY, Shin DH, Moon JW, Kang SM, Hahn CH, Kim YS, Chang J, Kim SK, Kim SK: The prevalence of human papillomavirus infection in Korean non-small cell lung cancer patients. Yonsei Med J 2007;48:69–77.
  183. Orjuela M, Castaneda VP, Ridaura C, Lecona E, Leal C, Abramson DH, Orlow I, Gerald W, Cordon-Cardo C: Presence of human papilloma virus in tumor tissue from children with retinoblastoma: an alternative mechanism for tumor development. Clin Cancer Res 2000;6:4010–4016.
  184. Palazzi MA, Yunes JA, Cardinalli IA, Stangenhaus GP, Brandalise SR, Ferreira SA, Sobrinho JS, Villa LL: Detection of oncogenic human papillomavirus in sporadic retinoblastoma. Acta Ophthalmol Scand 2003;81:396–398.
  185. Montoya-Fuentes H, Ramirez-Munoz M, Villar-Calvo V, Suarez-Rincon AE, Ornelas-Aguirre JM, Vazquez-Camacho G, Orbach-Arbouys S, Bravo-Cuellar A, Sanchez-Corona J: Identification of DNA sequences and viral proteins of 6 human papillomavirus types in retinoblastoma tissue. Anticancer Res 2003;23:2853–2862.
  186. Gillison ML, Chen R, Goshu E, Rushlow D, Chen N, Banister C, Creek KE, Gallie BL: Human retinoblastoma is not caused by known pRb-inactivating human DNA tumor viruses. Int J Cancer 2007;120:1482–1490.
  187. Di Lonardo A, Venuti A, Marcante ML: Human papillomavirus in breast cancer. Breast Cancer Res Treat 1992;21:95–100.
  188. Hennig EM, Nesland JM, Di Lonardo A, Venuti A: Multiple primary cancers and HPV infection: are they related? J Exp Clin Cancer Res 1999;18:53–54.
  189. Hennig EM, Suo Z, Thoresen S, Holm R, Kvinnsland S, Nesland JM: Human papillomavirus 16 in breast cancer of women treated for high grade cervical intraepithelial neoplasia (CIN III). Breast Cancer Res Treat 1999;53:121–135.
  190. Yu Y, Morimoto T, Sasa M, Okazaki K, Harada Y, Fujiwara T, Irie Y, Takahashi E, Tanigami A, Izumi K: Human papillomavirus type 33 DNA in breast cancer in Chinese. Breast Cancer 2000;7:33–36.
  191. Li T, Lu ZM, Guo M, Wu QJ, Chen KN, Xing HP, Mei Q, Ke Y: p53 codon 72 polymorphism (C/G) and the risk of human papillomavirus-associated carcinomas in China. Cancer 2002;95:2571–2576.
  192. Damin AP, Karam R, Zettler CG, Caleffi M, Alexandre CO: Evidence for an association of human papillomavirus and breast carcinomas. Breast Cancer Res Treat 2004;84:131–137.
  193. de Villiers EM, Sandstrom RE, zur Hausen H, Buck CE: Presence of papillomavirus sequences in condylomatous lesions of the mamillae and in invasive carcinoma of the breast. Breast Cancer Res 2005;7:R1–R11.
  194. Kan CY, Iacopetta BJ, Lawson JS, Whitaker NJ: Identification of human papillomavirus DNA gene sequences in human breast cancer. Br J Cancer 2005;93:946–948.
  195. Wrede D, Luqmani YA, Coombes RC, Vousden KH: Absence of HPV 16 and 18 DNA in breast cancer. Br J Cancer 1992;65:891–894.
  196. Bratthauer GL, Tavassoli FA, O’Leary TJ: Etiology of breast carcinoma: no apparent role for papillomavirus types 6/11/16/18. Pathol Res Pract 1992;188:384–386.
  197. Gopalkrishna V, Singh UR, Sodhani P, Sharma JK, Hedau ST, Mandal AK, Das BC: Absence of human papillomavirus DNA in breast cancer as revealed by polymerase chain reaction. Breast Cancer Res Treat 1992;39:197–202.
  198. de Cremoux P, Thioux M, Lebigot I, Sigal-Zafrani B, Salmon R, Sastre-Garau X; Institut Curie Breast Group: No evidence of human papillomavirus DNA sequences in invasive breast carcinoma. Breast Cancer Res Treat 2008;109:55–58.
  199. McNicol PJ, Dodd JG: Detection of papillomavirus DNA in human prostatic tissue by Southern blot analysis. Can J Microbiol 1990;36:359–362.
  200. Anwar K, Nakakuki K, Shiraishi T, et al: Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res 1992;52:5991–5996.
  201. Dillner J, Knekt P, Boman J, Lehtinen M, Af Geijersstam V, Sapp M, et al: Seroepidemiological association between human-papillomavirus infection and risk of prostate cancer. Int J Cancer 1998;75:564–567.
  202. McNicol PJ, Dodd JG: Detection of human papillomavirus DNA in prostate gland tissue by using the polymerase chain reaction amplification assay. J Clin Microbiol 1990;28:409–413.
  203. McNicol PJ, Dodd JG: High prevalence of human papillomavirus in prostate tissues. J Urol 1991;145:850–853.
  204. Masood S, Rhatigan RM, Powell S, et al: Human papillomavirus in prostatic cancer: no evidence found by in situ DNA hybridization. South Med J 1991;84:235–236.
  205. Effert PJ, Frye RA, Neubauer A, et al: Human papillomavirus types 16 and 18 are not involved in human prostate carcinogenesis analysis of archival human prostate cancer specimens by differential polymerase chain reaction. J Urol 1992;147:192–196.
  206. Wideroff L, Schottenfeld D, Carey TE, et al: Human papillomavirus DNA in malignant and hyperplastic prostate tissue of black and white males. Prostate 1996;28:117–123.
  207. Strickler H, Burk R, Shah K, Viscidi R, Jackson A, Pizza G, et al: A multifaceted study of human papillomavirus and prostate carcinoma. Cancer 1998;82:1118–1125.
  208. Strickler H, Goedert J: Sexual behavior and evidence for an infectious cause of prostate cancer. Epidemiol Rev 2001;23:144–151.
  209. Dennis LK, Dawson DV: Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 2002;13:72–79.
  210. Sitas F, Urban M, Stein L, Beral V, Ruff P, Hale M, Patel M, O’Connell D, Yu XQ, Verzijden A, Marais D, Williamson AL: The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population. Infect Agent Cancer 2007;2:6.
  211. Sutcliffe S, Giovannucci E, Gaydos CA, Viscidi RP, Jenkins FJ, Zenilman JM, Jacobson LP, De Marzo AM, Willett WC, Platz EA: Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2007;16:1573–1580.
  212. Kataoka A, Nishida T, Sugiyama T, Hori K, Honda S, Yakushiji M: Squamous cell carcinoma of the endometrium with human papillomavirus type 31 and without tumor suppressor gene p53 mutation. Gynecol Oncol 1997;65:180–184.
  213. Wu QJ, Guo M, Lu ZM, Li T, Qiao HZ, Ke Y: Detection of human papillomavirus-16 in ovarian malignancy. Br J Cancer 2003;89:672–675.
  214. Atalay F, Taskiran C, Taner MZ, Pak I, Or M, Tuncer S: Detection of human papillomavirus DNA and genotyping in patients with epithelial ovarian carcinoma. J Obstet Gynaecol Res 2007;33:823–828.
  215. McLellan R, Buscema J, Guerrero E, Shah KV, Woodruff JD, Currie JL: Investigation of ovarian neoplasia of low malignant potential for human papillomavirus. Gynecol Oncol 1990;38:383–385.
  216. Anttila M, Syrjänen S, Ji H, Saarikoski S, Syrjänen K: Failure to demonstrate human papillomavirus DNA in epithelial ovarian cancer by general primer PCR. Gynecol Oncol 1999;72:337–341.
  217. Yang HJ, Liu VW, Tsang PC, Yip AM, Ng TY, Cheung AN, Ngan HY: Comparison of human papillomavirus DNA levels in gynecological cancers: implication for cancer development. Tumour Biol 2003;24:310–316.
  218. Konidaris S, Kouskouni EE, Panoskaltsis T, Kreatsas G, Patsouris ES, Sarivalassis A, Nonni A, Lazaris AC: Human papillomavirus infection in malignant and benign gynaecological conditions: a study in Greek women. Health Care Women Int 2007;28:182–191.
  219. Kirgan D, Manalo P, Hall M, McGregor B: Association of human papillomavirus and colon neoplasms. Arch Surg 1990;125:862–865.
  220. McGregor B, Byrne P, Kirgan D, Albright J, Manalo P, Hall M: Confirmation of the association of human papillomavirus with human colon cancer. Am J Surg 1993;166:738–742.
  221. Cheng JY, Sheu LF, Meng CL, Lee WH, Lin JC: Detection of human papillomavirus DNA in colorectal carcinomas by polymerase chain reaction. Gut 1995;37:87–90.
  222. Salepci T, Yazici H, Topuz E, et al: Detection of human papillomavirus DNA in human colorectal cancers by polymerase chain reaction. Proc Annu Meet Am Soc Clin Oncol 1999;18:2389.
  223. Lee YM, Leu SY, Chiang H, Chiang H, Fung CP, Liu WT: Human papillomavirus type 18 in colorectal cancer. J Microbiol Immunol Infect 2001;34:87–91.
  224. Pérez LO, Abba MC, Laguens RM, Golijow CD: Analysis of adenocarcinoma of the colon and rectum: detection of human papillomavirus (HPV) DNA by polymerase chain reaction. Colorectal Dis 2005;7:492–495.
  225. Damin DC, Caetano MB, Rosito MA, Schwartsmann G, Damin AS, Frazzon AP, Ruppenthal RD, Alexandre CO: Evidence for an association of human papillomavirus infection and colorectal cancer. Eur J Surg Oncol 2007;33:569–574.
  226. Shroyer KR, Kim JG, Manos MM, Greer CE, Pearlman NW, Franklin WA: Papillomavirus found in anorectal squamous carcinoma, not in colon adenocarcinoma. Arch Surg 1992;127:741–744.
  227. Shah KV, Daniel RW, Simons JW, Vogelstein B: Investigation of colon cancers for human papillomavirus genomic sequences by polymerase chain reaction. J Surg Oncol 1992;51:5–7.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50